Overview ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD) Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary Evaluation of the effect of ADX10059 on symptom control in patients with gastroesophageal reflux. Phase: Phase 2 Details Lead Sponsor: Addex Pharma S.A.